Medtronic (MDT) is offering an attractive entry point following an
"overblown" reaction to its top-line fiscal Q3 miss and reiterated guidance, RBC Capital Markets said in a Tuesday note.
"Investor reaction to FQ3 results and latest guide appear overblown," RBC analysts, including Shagun Singh, said.
They said catalysts such as the Symplicity Spyral Renal Denervation System and surgical robotics keep them positive.
"We are buyers on weakness," the analysts said. "MDT's steep discount to the market is still not justified in our view."
RBC kept its outperform rating and $105 price target.
Price: 86.23, Change: +0.16, Percent Change: +0.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.